Clean Phase 3 win in post-bariatric hypoglycemia positions avexitide for NDA filing; approval converts a no-revenue rebuilding story into a commercial franchise

Amylyx is a clinical-stage biopharmaceutical company developing avexitide, a targeted therapy for dangerously low blood sugar episodes that occur after weight-loss surgery, which is not yet approved.

Amylyx rebuilt after withdrawing AMX0035 from ALS, and avexitide's Phase 3 LUCIDITY trial just delivered a 55% reduction in composite hypoglycemic events versus placebo with a p-value of 0.000003, hitting all secondary endpoints. The thesis resolves on whether FDA grants approval on the NDA filing planned by year-end 2026, with Breakthrough Therapy Designation in hand but no prior approval anchoring regulatory expectations. The single most important risk is that this is a first approval attempt on Phase 3 data alone in a condition without an established regulatory template, while burn of roughly $46 million per quarter leaves runway into 2028, covering the likely decision window with limited margin.